The strategic partnership sees two separate financial deals for the pair of oncology assets. Rights to Kelun’s integrin ...

China’s growing capabilities have drawn pharmaceutical multinationals to the country to either buy or co-develop innovative drugs. China’s share of out-licensing deals to the US and Europe has risen ...

China’s focus on first or best-in-class oncology drugs and innovative R&D will position it well in 2026 and beyond.

Acute myeloid leukemia (AML) is an aggressive cancer of the blood and bone marrow, characterized by rapid growth of abnormal white blood cells. As AML primarily affects older adults, the global rise ...

Just 10 years ago, there was virtually no biopharmaceutical industry in China. But now, almost all global big pharma ...

Frederick, MD — Gov. Wes Moore on Friday announced that AstraZeneca will invest $2 billion to expand its operations in Maryland in what he described as the “single largest private investment in ...

DEVELOPMENTS FROM FREDERICK. THE INVESTMENT PROVIDES AN ECONOMIC SHOT IN THE ARM, CREATES JOBS AND BOOSTS THE STATE’S EFFORT TO EXPAND MARYLAND’S LIFE SCIENCES SECTOR. TODAY IS ABOUT SHOWING THAT WE ...

Wondering if AstraZeneca is still a buy after its big run, or if the easy money has already been made? This breakdown will walk you through whether the current share price still makes sense. The stock ...

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca today announces plans to invest $2 billion to expand its long-standing manufacturing footprint in Maryland. This includes a significant expansion of its ...

Investment supports 2,600 jobs, including 300 highly skilled positions AstraZeneca's expansion aligns with Trump's domestic manufacturing push Announcement is part of drugmaker's $50 billion ...

On December 12, 2025, the US Food and Drug Administration approved Johnson & Johnson subsidiary Janssen Biotech’s Akeega (niraparib and abiraterone acetate with prednisone for adults with deleterious ...

The pharmaceutical giant is plowing billions of dollars into expanding its drug-making capacity. It has ambitious plans for two facilities in Maryland. AstraZeneca announced it is investing $2 billion ...